Helicobacter pylori

Helicobacter pylori, known for its distinctive spiral shape, is a Gram-negative, micro-acidophilic bacterium that is primarily found in the stomach. It utilizes certain advanced strategies to survive in the severely acidic environment of the stomach. H. pylori infection can lead to stomach complications such as gastritis, peptic ulcer disease and stomach cancer.

Epidemiology

Helicobacter pylori infection

Various epidemiological studies have shown that infections caused by Helicobacter pylori are jeopardizing health worldwide.

• About half of the global population is infected by this bacterium, which is spreading at an increasing rate in underdeveloped countries due to poor sanitation and low socio-economic levels.
• Although it is mainly contracted during childhood, symptoms can occur at any other stage.
• The exact mode of transmission of H. pylori infection is not known, but it appears to be spread from person to person.
• Recurrence of H. pylori after successful clearance is relatively unlikely, but it can still occur.

Antibiotic Resistance

The rapid mutation of the H. pylori's genes drastically heightens its antibiotic resistance. This bacterium exhibits its resistance by,

Rapid mutation of H. pylori genes greatly enhances its antibiotic resistance. The resistance mechanism of H. pylori is able to manifest resistance by

• Altering antibiotic targets.
• Reducing permeability and promoting drug efflux.
• Inactivating the antibiotic.
• Forming biofilms.

Its potential to generate highly diverse populations is one of the reasons for the complications of drug resistance.

Treatment Options

Antibiotic therapy

Antibiotics such as fluoroquinolones and macrolides are empirically used in the clinical treatment of infectious gastroenteritis, but the emergence of Campylobacter multidrug resistance and the increase in the degree of resistance have posed a serious challenge to clinical drug use.

Potential treatment options

• Utilizing natural products
• Implementing phage therapy
• Employing vaccine strategy
• Applying antimicrobial peptides

Our Capabilities

As one of the pioneers in the field of preclinical CRO, Ace Therapeutics is aggressively developing strategies to address the high level of antibiotic resistance in Helicobacter pylori. Our resourceful research and development team is working tirelessly to understand the resistance mechanisms and developing targeted therapies.

In Conclusion

The global increase in H. pylori cases and growing antibiotic resistance has highlighted the urgent need for innovative treatment strategies, and Ace Therapeutics is committed to leading the way in alleviating this problem. Our dedicated team of researchers is continually exploring the complexities of H. pylori in order to develop effective treatment options for our patients.

Your collaboration will play a key role in our fight against H. pylori. We invite you to partner with us for a healthier future.

Reference

1. Eusebi LH; et al. (2014). Epidemiology of Helicobacter pylori infection. Helicobacter. 19 Suppl 1:1-5.